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Background. About 10% of pregnancies are complicated by previously unknown impairment of glucose metabolism, which is
deﬁned as gestational diabetes. There are little data available on prevalence of thyroid disorders in patients aﬀected by gestational
diabetes, and about their postgestational thyroid function and autoimmunity. We therefore investigated pancreatic and thyroid
autoimmunity in gestational diabetic patients and in women who had had a previous gestational diabetic pregnancy. Methods.W e
investigated 126 pregnant women at the time of a 100-g oral glucose tolerance test: 91 were classiﬁed as gestational diabetics, and
35 were negative (controls). We also studied 69 women who had delivered a baby 18–120 months prior to this investigation and
who were classiﬁed at that time gestational diabetics (38 women) or normally pregnant (31 women; controls). Results. Our data
show no diﬀerences for both thyroid function and prevalence of autoimmune disorders during pregnancy; however, a signiﬁcant
increase in thyroid autoimmunity was seen in women previously aﬀected by gestational diabetes. This increased prevalence of
thyroid autoimmunity was not associated with the development of impaired glucose metabolism after pregnancy. Conclusions.
Our data suggest that maternal hyperglycemia is a risk factor for the development of thyroid autoimmunity, a conclusion that
should now be conﬁrmed in a larger cohort of patients.
1.Introduction
Gestational diabetes (GDM) is deﬁned as any degree of
carbohydrate intolerance that is ﬁrst diagnosed during
pregnancy [1]. The prevalence of GDM ranges between 1%
and 14% [1–3] ,a n di ti sm o s tf r e q u e n ti nw o m e na g e d≥35
years in the second trimester of pregnancy. In a minority
(<10%) of patients, the need for insulin therapy continues
after delivery, and in these cases detection of anti-glutamic-
acid-decarboxylase- (GAD-) 65 antibodies (GAD65-Ab) is
common, and so GDM is considered the onset of type
1 diabetes [4–6]. Increased incidence of organ-speciﬁc
autoimmunity towards endocrine cells other than β-cells
has been described in type 1 diabetes patients [7], and it is
believed to be caused by a genetic propensity to autoimmune
disorders. In the majority of patients, however, GDM is
believed to be caused by β-cell dysfunction that occurs on a
background of chronic insulin resistance. Although in these
patients GDM usually resolves after delivery, up to 70% of
them develop overt type 2 diabetes mellitus within 10 years
[4, 8].
Recent studies have reported increased incidence of
thyroid autoimmunity in type 2 diabetes [9, 10], thus
implying that diabetes can trigger the onset of thyroid
autoimmunity. Few studies have, however, evaluated the
prevalence of thyroid dysfunction and autoimmunity in2 International Journal of Endocrinology
women with GDM [11–13]. Moreover, little is known
about thyroid autoimmunity in post-GDM patients, who
usually return to normal glucose control after delivery. In
our opinion, GDM oﬀers a good opportunity to study if
diabetes and hyperglycemia might predispose to thyroid
autoimmunity.
In the present study, we therefore investigated (1) pan-
creatic and thyroid autoimmunity in GDM patients and (2)
pancreatic and thyroid autoimmunity in women with previ-
ous GDM.
2. Patientsand Methods
2.1. Patients. One-hundred-and-ninety-ﬁve women (aged
18to51)whowerereferredtotheDiabetic OutpatientClinic
of the “Santo Spirito” Pescara Hospital were evaluated; none
of these patients had a hyperglycemic disease before gesta-
tion. Initially, 126 consecutive pregnant (group A) women
were evaluated at the 14th to 34th weeks of pregnancy at the
timeofa100goralglucosetolerancetest(OGTT),whichwas
interpreted according to the O’ Sullivan and Mahan criteria
revised by Carpenter and Coustan [14–16]. According to the
OGTT results, these patients were further subdivided into
two groups.
(i) A1: 91 patients (mean age, 33±10 years) with a posi-
tive OGTT, considered as women aﬀected by GDM.
(ii) A2: 35 women (mean age, 29±11 years) with a nega-
tive OGTT, considered as normally pregnant women
(controls).
The remaining 69 women (group B) had delivered a baby
18 months to 120 months before this study. During their
pregnancy, they had been evaluated by an OGTT and were
diagnosed accordingly as having been aﬀected, or not, by
GDM. For the purpose of this study, these patients were also
further subdivided into two groups.
(i) B1: 38 patients (mean age, 40 ± 11 years) with a
positive OGTT during their pregnancy, considered
as women previously aﬀected by GDM. At the time
of the present study (18–120 months after delivery),
they were evaluated again for thyroid function and
glucose metabolism by a 75g OGTT.
(ii) B2: 31 women (mean age, 40 ± 5.7y e a r s )w i t ha
negative OGTT during their pregnancy who did not
develop diabetes after delivery, considered as previ-
ously normal pregnancy controls; the time elapsed
since their delivery was 18 months to 96 months.
They were enrolled as mothers whose children were
attending the family care clinic of two pediatricians
operating in the Pescara area.
Women with a positive history for thyroid diseases and
who had taken any drug known to interfere with thyroid
function or the immune system were excluded from the
study. None of the subjects enrolled in the study were
evaluated twice; therefore, none of the patients in group A
were also included in group B. All women with elevated TSH
levels in groups A1 and A2 were treated with L-thyroxine;
for women of group B1 we individually evaluated the option
of treatment. Informed consent was obtained from all of the
participants in the study.
2.2. Methods. Commercially available kits were used to
determine the levels of free thyroxine (FT4) (immunoﬂuo-
rometric assay; normal range 0.76–1.42ng/dL; Perkin Elmer
Italiaspa,Monza,Italy),thyrotropin(TSH)(immunoﬂuoro-
metric assay TSH ultra; normal range 0.4–4.2μIU/L; Perkin
Elmer Italia spa, Monza, Italy), antiperoxidase antibod-
ies (TPO) (TPO-Ab radioimmunoassay kit; normal value
<15IU/mL; Becton, Dickinson and Co, Franklin Lakes, NJ,
USA), antithyroglobulin antibodies (Tg) (Tg-Ab Elisa Kit;
normal value <100IU/mL; Alpco Diagnostics, Salem, NH,
USA), and antiglutamic acid decarboxylase-65 antibodies
(GAD65-Ab radioimmunoassay; normal value <1IU/mL;
Adaltis Italia spa, Casalecchio di Reno, Italy).
Stimulating TSH receptor antibodies (TSHr-Abs) were
calculated using a biological assay, as previously described
[17]. Brieﬂy, Chinese hamster ovary (CHO) cells were
subjected to a two-step double stable transfection: in the ﬁrst
step, the cells were transfected with a CRE-luc construct,
which makes the cells particularly sensitive to changes in
cAMP levels. In the second step, the cells were transfected
with wild-type human TSHr. These cells were maintained
in Ham’s F12 nonessential amino acids supplemented
with 10% fetal calf serum and penicillin/streptomycin
(1U/mL/1mg/mL, resp.) for 24 hours, which was then
replaced with starvation media (Hank’s balanced salt solu-
tion; no fetal calf serum) for another 24 hours. All of the cells
were maintained at 37◦C, in 5% CO2 and at 95% relative
humidity. Cut-oﬀ of normal values was determined in the
following manner: the mean of ≥5 samples from normal
subjects was calculated. The standard deviation between
these normal samples was determined, and this value was
multiplied by two and added to the calculated mean. The
cut-oﬀ value obtained in this way was arbitrarily considered
equal to 1 unit (AU). The luciferase activity was determined
using the Bright-Glow reagent, by measurement of the light
output using a single-tube luminometer. Interassay and
intra-assay variability were <5%.
Student’ T tests were used with unpaired data, and
Fisher’s exact tests and χ2 tests were performed.
3. Results
The presence of pancreatic autoimmunity in the cohort
of patients was evaluated by determination of GAD65-Ab
levels. We observed that 3 (3.3%) patients were positive for
GAD65-Ab in group A1, 2 of whom had low GAD-65 titers
(<2IU/mL), while the third had a GAD-65 titer of 33IU/mL.
All of the patients in group A2 were negative for GAD65-
Ab. In the group of previously gestational women (B1), 2
(5.3%) patients had GAD65-Ab-positive values, 1 of whom
had low level positivity (<2IU/mL), and the second, who
had a GAD65-Ab value of 16IU/mL, was diagnosed as typeInternational Journal of Endocrinology 3
Table 1: Clinical characteristics and laboratory data of the four groups of women evaluated.
Groups
A1 (n = 91) A2 (n = 35) B1 (n = 38) B2 (n = 31)
Mean age (years) 33 ±10 29 ±11 40 ±11 40 ±6
Time from delivery (range, months) — — 18–120 18–96
BMI at OGTT 29.8 ±4.02 8 .1 ±4.72 7 .2 ±2.2—
BMI at follow-up — — 24.1 ±2.82 3 .5 ±3.7
GAD65-Ab positivity [n (%)] 3 (3.3) 0 2 (5.3) 0
Mean FT4 (ng/dL) 0.82 ±0.13 0.83 ±0.09 0.93 ±0.21 0.92 ±0.17
Mean TSH (mIU/L) 1.46 ±1.02 1.90 ±1.42 .45 ±4.32 1.44 ±0.92
TSH < 0.4mIU/L [n (%)] 8 (8.8) 2 (5.7) 5 (13.1) 2 (6.5)
TSH > 4.2mIU/L [n (%)] 2 (2.2) 2 (5.7) 4 (10.5) 1 (3.2)
Overall abnormal TSH [n (%)] 10 (11.0) 4 (11.4) 9 (23.7)∗ 3 (9.7)
T h y r o i dA bp o s i t i v i t y[ n (%)] 16 (17.6) 5 (14.4) 12 (31.6)∗ 3 (9.7)
Abnormal TSH + thyroid Ab positivity [n (%)] 3 (3.3) 0 (−) 7 (18.4)∗∗ 1 (3.2)
∗P < 0.05 versus groups A1 and B2; ∗∗P < 0.05 versus groups B2 and P<0.001 versus group A1. Where indicated, data are means ± SD.
1 diabetic and is on insulin treatment. None of the B2 group
(controlgroup)showedpositiveGAD65-Abvalues(Table 1).
The mean TSH values were not signiﬁcantly diﬀerent
between the four groups (1.46±1.02 versus 1.90±1.4mIU/L
in groups A1 and A2, resp., and 2.45 ± 4.32 versus 1.44 ±
0.9 2 m I U / Li ng r o u p sB 1a n dB 2 ,r e s p . )( Table 1). No
signiﬁcant diﬀerences were seen between the four groups
either considering these mean TSH values or separately
evaluating the TSH values as below and above the normal
range. However, if we consider the overall incidence of
abnormal TSH values, a signiﬁcantly higher incidence (P<
0.05) was seen for group B1 versus both groups A1 and B2
(Figure 1).
The FT4 levels were not signiﬁcantly diﬀerent when
comparing either gestational versus normal pregnancies
(0.82 ± 0.13 versus 0.83 ± 0.09ng/dL for groups A1 and A2,
resp.) or postgestational versus controls (0.94 ± 0.21 versus
0.92±0.17ng/dL for groups B1 and B2, resp.) (Table 1). Our
data conﬁrm the signiﬁcantly lower FT4 values in pregnancy
(0.82 ± 0.13 versus 0.93 ± 0.19ng/dL, resp.; P<0.001);
however, FT4 was within the normal range in all of the
pregnant women if the values are modiﬁed according to
pregnancy [18].
Anti-TPO-Abs were detected in 16 (17.6%) patients in
group A1, 5 (14.3%) in group A2, 10 (26.3%) in group B1,
and 3 (9.7%) in group B2. Anti-Tg-Abs were detected in
6 (6.6%) patients in group A1, 1 (2.8%) in group A2, 6
(15.8%) in group B1, and 1 (3.2%) in group B2. Moreover,
1 patient in group B1 (of previously gestational women)
had positive stimulating TSHr-Ab, with a suppressed TSH
(<0.01μIU/mL)andnegativeTPO-Ab.Therefore,theoverall
incidence of thyroid autoimmunity (12/38, 31.6%) in group
B1 was signiﬁcantly (P<0.0 5 )gr e a t e rt h a ni ngr o u p sB 2a n d
A1(Figure 1).Noothersubjectswerepositiveforstimulating
TSHr-Ab. Only 1 patient (in group A1) had positivity for
both GAD65-Ab and TPO-Ab.
When considering the coincident presence of thyroid
autoimmunity and abnormal TSH values, it is interesting
to note that the combination of both was observed in 3/91
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Figure 1: Patients (as percentages within each single group)
aﬀected by thyroid autoimmunity (TPO-Ab, Tg-Ab, and TSHr-Ab
positivity), thyroid dysfunction (TSH < 0.4mIU/L or >4.2mIU/L)
or the combination. Group A1: GDM pregnant women; group A2:
non-GDM pregnant women; group B1: post-GDM women; group
B2: healthy mothers.
∗P < 0.05 versus groups A1 and B2;
∗∗P <
0.05 versus group B2 and P<0.001 versus group A1.
(3.3%) patients in group A1, 0/35 (0.0%) in group A2, 7/38
(18.4%) in group B1, and 1/31 (3.3%) in group B2. The
association of abnormal TSH and TPO-Ab positivity was
signiﬁcantly greater in group B1 versus both groups B2 (P<
0.05) and A1 (P<0.001) (Table 1 and Figure 1).
The possibility that thyroid Ab positivity is associated
with the onset of permanently impaired glucose metabolism
in the previously gestational women (Table 2) was also
considered. Here, 18/38 (47.4%) previously gestational
women showed hyperglycemic disease at the follow-up;4 International Journal of Endocrinology
Table 2: Glucose abnormalities and thyroid autoimmunity in post-
GDM women (group B1).
Thyroid
autoimmunity Condition
Glucose
metabolism
[n (%)]
T h y r o i dA bp o s i t i v e
(n = 12)
Normal 5 (41.7)
Type 1 diabetes mellitus 1 (8.3)
Type 2 diabetes mellitus 2 (16.7)
Impaired glucose
tolerance 3 (25)
Impaired fasting glucose 1 (8.3)
T h y r o i dA bn e g a t i v e
(n = 26)
Normal 15 (57.7)
Type 1 diabetes mellitus 1 (3.8)
Type 2 diabetes mellitus 2 (7.7)
Impaired glucose
tolerance 8 (30.8)
Impaired fasting glucose —
these patients were widely distributed between thyroid
autoimmune and nonautoimmune patients. Indeed, 7/12
(58.3%) women with thyroid Ab (TPO-Ab and TSHr-Ab)
positivity showed hyperglycemia, while 11/26 (42.3%) with
negative thyroid Abs had impaired glucose metabolism; no
statistically signiﬁcant diﬀerences were detected between
these two groups.
4. Discussion
The prevalence of pancreatic autoimmunity in GDM has
been widely investigated [3, 5, 6, 19], and it has been shown
to diﬀer for racial and geographic reasons. In the present
study, GAD65-Abs were detected in 3.3% of our population,
a level that is in agreement with several previous reports
[2,3,5,6,19].Inourstudywehavechosentodetermineonly
anti-GAD,becauseGADautoantibodiesaremarkerswiththe
highest diagnostic sensitivity in LADA, so they should be
used to identify such patient [20].
Fewer studies have investigated the prevalence of thyroid
autoimmunity during GDM: most of these did not show a
signiﬁcant increase [13, 21], although few reports [11, 22]
showed a higher risk of thyroid autoimmunity in women
with a family history of diabetes and thyroid diseases. The
present study also shows no signiﬁcant diﬀerences.
The mean TSH value of the GDM patients was similar to
that seen in normally pregnant women, and no diﬀerences
were seen relating to the prevalence of abnormal TSH values
between these two groups. At the same time, the FT4
levels were not signiﬁcantly diﬀerent. In summary, it can
be concluded that no diﬀerences in thyroid function and
autoimmunity were detected in the present study in GDM
patients, as compared with normally pregnant women.
To our knowledge, little data are available on the
prevalence of thyroid autoimmunity in women with pre-
vious GDM. We found an increased frequency of thyroid
antibodies in patients with previous GDM; indeed, 31.6% of
our patients were positive for TPO-Ab, Tg-Abs or TSHr-Ab,
as compared with 9.7% for women with previously normal
pregnancies. We would also underline that in one patient,
thyroid autoimmunity was only revealed by the TSHr-Ab
assay. The presence of the TSHr-Ab as the only marker
of thyroid autoimmunity has been described previously for
a population of type 1 diabetes patients [23]; however,
GAD65-Abs were negative in our patients, and there is no
need at present for insulin therapy. The TSHr-Ab assay has
thereforetobeconsideredasausefultooltorevealsubclinical
autoimmune hyperthyroidism whenever TSH is below the
normal range, even if TPO-Abs are negative and there is no
other sign of endocrine autoimmunity.
An association of thyroid dysfunction and Ab positivity
was detected more frequently in the previously gestational
women(7/38[18.4%]ingroupB1,and1/31[3.3%]ingroup
B2). On the basis of our data, it can be speculated that
an increase in thyroid autoimmunity occurs in post-GDM
women and that this phenomenon is relevant enough to
cause subclinical thyroid dysfunction.
An association between autoimmune diabetes (type 1
and latent autoimmune diabetes) and other organ-speciﬁc
autoimmune disorders has been widely described [7, 24];
however, in the present study, only 1 woman showed
positivity for both pancreatic and thyroid autoimmunities.
A common (pancreatic and thyroid) autoimmune trait
appears therefore an unlikely explanation for the increased
prevalence of thyroid autoimmunity in our post-GDM
patients. Igawa et al. [25] suggested that the clinical
association between chronic autoimmune thyroiditis and
type 2 diabetes is related to a common antigen that is
shared by pancreatic β-cells and thyroid follicular cells.
More recently, we have shown that a 10mM increase in
glucose levels in cultured thyroid cells can upregulate major
histocompatibility complex (MHC) class I expression [26].
We therefore hypothesized that this phenomenon causes the
thyrocyte to become an antigen-presenting cell and possibly
to overcome self-tolerance. It has indeed been shown that
elevated levels of MHC molecules, which increase thyroid
antigen presentation, can trigger thyroid autoimmunity in
animal models [27, 28].
In accordance with this observation, we speculate that
hyperglycemia at the time of pregnancy or immediately after
delivery triggered the autoimmune disorder in our patients.
If this is the case, GDM represents a unique chance to
evaluateprogressionofthyroidautoimmunityfromitsonset.
It has to be emphasized, however, that the present study
and our speculative explanation should still be considered as
a preliminary step. In our study the diagnosis of GDM was
carried out by OGTT with 100g of glucose, and as is known
new diagnostic criteria suggested by IADPSG [29] and ADA
have been recently introduced. We cannot say whether the
conduct would have been the same with new criteria. In
fact the new criteria for diagnosing GDM identiﬁed a group
of women previously classiﬁable as normal according to
the 4th International Workshop Conference criteria, but
revealing metabolic characteristics and pregnancy outcomes
resemblingthoseofwomenwhowouldhavebeenconsidered
to have gestational diabetes by the previous criteria [30].International Journal of Endocrinology 5
A major limit of this study is indeed the relatively small
number of subjects evaluated. Therefore, observations on a
larger population are needed to conﬁrm our data.
Inthiscontext,wealsocannotruleoutthepossibilitythat
progression towards hyperglycemic disease after delivery can
further facilitate the onset of thyroid autoimmune disease;
the small number of patients did not allow the reaching
of statistical signiﬁcance, even if a higher percentage of
patients with impaired glucose metabolism showed thyroid
Ab positivity (58.3% versus 42.3%). In a 20-year follow-up,
M¨ annist¨ o and colleagues [31] showed that instead of thyroid
antibodies presence of overt hypothyroidism poses risk of
diabetes. On the other side, the presence of TPO-Ab is not
predisposing to the development of GDM [32]. Indeed, in a
large study that included more than 600 pregnant women,
GDM was seen in 8.1% of the women with TPO-antibody
positivity, as compared to 6.8% without the TPO antibody,
and this diﬀerence was not signiﬁcant.
In summary, the main and new ﬁnding from our
study is the higher prevalence of thyroid autoimmunity in
women who have had previous GDM; in the same group,
thyroid dysfunction is also more prevalent. We speculate that
gestational hyperglycemia can trigger thyroid autoimmunity.
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